Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Carrión-Barberà, María Irene
- dc.contributor.author Triginer, Laura
- dc.contributor.author Tío, Laura
- dc.contributor.author Pérez-García, Carolina
- dc.contributor.author Ribes, Anna
- dc.contributor.author Abad, Victoria
- dc.contributor.author Pros Simón, Ana
- dc.contributor.author Bermúdez-López, Marcelino
- dc.contributor.author Castro-Boqué, Eva
- dc.contributor.author Lecube, Albert
- dc.contributor.author Valdivielso, Jose Manuel
- dc.contributor.author Ilervas Project Group
- dc.contributor.author Monfort, Jordi
- dc.contributor.author Salman-Monte, Tarek Carlos
- dc.date.accessioned 2025-06-04T06:18:41Z
- dc.date.available 2025-06-04T06:18:41Z
- dc.date.issued 2024
- dc.description.abstract Advanced glycation end-products (AGEs) may play a relevant role as inducers in the chronic inflammatory pathway present in immune-mediated diseases, such as systemic lupus erythematosus (SLE). AGEs concentrations have been associated, with discrepant results to date, with some parameters such as disease activity or accrual damage, suggesting their potential usefulness as biomarkers of the disease. Our objectives are to confirm differences in AGEs levels measured by cutaneous autofluorescence between SLE patients and healthy controls (HC) and to study their correlation with various disease parameters. Cross-sectional study, where AGEs levels were measured by skin autofluorescence, and SLE patients' data were compared with those of sex- and age-matched HC in a 1:3 proportion through a multiple linear regression model. Associations of AGEs levels with demographic and clinical data were analyzed through ANOVA tests. Both analyses were adjusted for confounders. AGEs levels in SLE patients were significantly higher than in HC (p < 0.001). We found statistically significant positive associations with SLE disease activity index (SLEDAI) and damage index (SDI), physician and patient global assessment, C-reactive protein, leukocyturia, complement C4, IL-6 and oral ulcers. We also found a negative statistically significant association with current positivity of anti-nuclear and anti-Ro60 antibodies. AGEs seem to have a contribution in LES pathophysiology, being associated with activity and damage and having a role as a new management and prognosis biomarker in this disease. The association with specific antibodies and disease manifestations may indicate a specific clinical phenotype related to higher or lower AGEs levels.
- dc.format.mimetype application/pdf
- dc.identifier.citation Carrión-Barberà I, Triginer L, Tío L, Pérez-García C, Ribes A, Abad V, et al. Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus. Int J Mol Sci. 2024 Mar 5;25(5):3022. DOI: 10.3390/ijms25053022
- dc.identifier.doi http://dx.doi.org/10.3390/ijms25053022
- dc.identifier.issn 1422-0067
- dc.identifier.uri http://hdl.handle.net/10230/70603
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Int J Mol Sci. 2024 Mar 5;25(5):3022
- dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Advanced glycation end products
- dc.subject.keyword Biomarkers
- dc.subject.keyword Cardiovascular disease
- dc.subject.keyword Systemic lupus erythematosus
- dc.title Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion